Deficiency of the E3 ubiquitin ligase UBE3A leads to the neurodevelopmental disorder Angelman syndrome (AS), while higher levels are linked to autism spectrum disorder. The mechanisms underlying the downstream effects of UBE3A loss or gain of function in these disorders are still not well understood, and treatments are still lacking.
Introduction
Deletions or loss-of-function mutations in the maternal allele of the UBE3A gene lead to Angelman syndrome (AS), a developmental neurological disorder in the Autism spectrum characterized by severe intellectual disability. The consequences of UBE3A dysfunction/loss and the mechanisms of the downstream effects of this gain or loss of functions are still not fully understood, and effective treatments are lacking. The AS mouse model, with loss of the Ube3a (Ube3a m-/p+ ) maternal allele, recapitulates many of the AS's symptoms, including motor and cognitive impairments closely correlated with reduced spine number and aberrant spine morphology (Dindot et al., 2008; Jana, 2012; Jiang et al., 1998; Kim et al., 2016; Koyavski et al., 2019; Yashiro et al., 2009 Yashiro et al., , 2009 ).
UBE3A appears to have a critical role in dendritic spine development and in their plasticity (Kim et al., 2016; Yashiro et al., 2009 ). In addition, Ube3a m-/p+ mice also have defective hippocampal longterm potentiation and dendritic spine density, in line with deficits in behavioral tasks (Dindot et al., 2008; van Woerden et al., 2007) . However, little is known about the neuronal function of the UBE3A in control condition and even less about the pathogenesis linked to UBE3A-related disorders. UBE3A plays a role in dendritic spine function/dysfunction, but the mechanisms that link E3 ubiquitin ligase UBE3A to dendritic spine are not clear yet.
To identify downstream effectors of UBE3A loss-of-function we studied the stress-JNK signaling pathway in Ube3a m−/p+ mice. Since c-Jun-N-terminal Kinase (JNK) signaling is an intracellular pathway strongly responsive in the brain to different stressors and plays a key role in brain development and maintenance (Antoniou and Borsello, 2010; Coffey, 2014) , we investigated whether the JNK pathway was involved in AS and in particular in AS synaptic dysfunction. JNK controls neuronal plasticity and memory formation (Coffey, 2014; Kumar et al., 2015) , synaptic functions and synaptic dysfunction (Biggi et al., 2017; Buccarello et al., 2018 Buccarello et al., , 2017 Sclip et al., 2014 Sclip et al., , 2013 Sclip et al., , 2011 . The JNK signaling pathway is activated in many different brain diseases such as stroke (Borsello et al., 2003; Vercelli et al., 2015) , epilepsy (Auladell et al., 2017; Zhuo et al., 2016) , Alzheimer's (Colombo et al., 2009; Okazawa and Estus, 2002; Ploia et al., 2011; Sclip et al., 2011 Sclip et al., , 2014 , Parkinson's (Kuan and Burke, 2005; Wang et al., 2014 Wang et al., , 2004 , Huntington's disease (Perrin et al., 2009) and Spinal Muscular Atrophy (Schellino et al., 2018) . Less is known about weeks of age, early in the pathology. JNK activation persists up to 23 weeks of age, when the disorder is more severe, suggesting long-lasting activation of this stress pathway. Ube3a m−/p+ mice also show a change in PSD biochemical marker levels related to JNK activation and behavioral deficits, suggesting an altered cytoarchitecture of the dendritic spines.
Synaptic injury is the first neurodegenerative event in brain diseases and understanding the molecular players leading to synaptic dysfunction will help in the development of tailored synapsetargeted therapies for neurodevelopmental disorders.
Here we identify JNK as an important kinase that regulates synaptic injury downstream UBE3A Animal treatment. All mice (Ube3a m−/p+ or wt) were injected intraperitoneally (ip) with D-JNKI1 (22 mg/kg) every 28 days from 7 to 23 weeks of age. Their weight was recorded before and after each dose. Mice were always treated at the same time of day (9:00-10:00 A.M.) in randomized order in a specific room inside the animal facility. Each single mouse was our experimental unit.
After behavioral tests the animals were euthanized and brains were dissected for biochemical analysis.
Behavioral tests.
rod was accelerated at a constant rate of 0.3 rpm/s from 3 rpm to 30 rpm for 5-min. The time (seconds) at which the animal fell from the bar was recorded. Three trials were run for each animal, with a 5-min rest between them, and the longest retention time was recorded. The mean latency to fall during the session was calculated and used in subsequent analysis.
-The Open Field Test (OF) was used to examine general spontaneous locomotion, as well as exploration, and the relative level of anxiety by exposing mice to a novel and an open space (Crawley, 1999; Seibenhener and Wooten, 2015; Walsh and Cummins, 1976) .
We used a grey OF box (40 × 40 × 40 cm) with the floor divided into 25 (8 × 8 cm) squares.
Animals were placed in the center of the arena, considered as a 'starting point', and their behavior was tracked with the activity monitoring system (Ethovision system) for 5 min. This short time was chosen to avoid further stress to mutant mice (30/group). The parameters analyzed as measures of spontaneous locomotor activity, exploratory activity and state of anxiety were: time spent in the inner zone (the nine central squares) and in the periphery of the arena (the sixteen peripheral squares), the number of crossings between the center and the periphery, the overall distance travelled, the velocity and the hypermobility.
-The novel-object recognition test (NORT) is a memory test based on spontaneous animal behavior without the need for stressful elements such as food or water deprivation or foot-shock (Antunes and Biala, 2012; Clarke et al., 2010) . The NORT was conducted in an open-field arena (40 × 40 × 40 cm) with the floor divided into 25 squares by black lines; three stimulus objects of similar size were used: a black plastic cylinder (4 × 5 cm), a glass vial with a white cup (3 × 6 cm), and a metal cube (3 × 5 cm). The first phase of the NORT is the habituation trial in the Open Field Test, during which the animals were placed in the empty arena for 5 min. The next day, mice were placed again in the same arena containing two identical objects (familiarization phase/second phase). The objects were randomly selected to avoid bias among animals and between groups. Objects and positions were counterbalanced across experiments and behavioral trials. Exploration was recorded with the Results were expressed as a discrimination index (DI) (seconds spent on novel -seconds spent on familiar)/(total time spent on objects). Animals with no cognitive impairment spent longer investigating the novel object, giving a higher DI. We used 30 animals for each experimental group.
Biochemical analysis: Subcellular fractionation (TIF). For biochemical analysis, at the end of behavioral tests, mice were euthanized by cervical dislocation (Angus et al., 2008; Carbone et al., 2012) . Brains were removed and specific areas (cortex, hippocampus and cerebellum) were hippocampus and cerebellum were also measured at 23 weeks of age to determine the importance of stress signaling in the progression of Ube3a m−/p+ pathology. JNK activity was significantly higher in Ube3a m−/p+ mice than in age-matched wt mice (39% in the hippocampus, 27% in the cortex and 25% in the cerebellum, p<0.0001; p<0.0001; p<0.0001, Fig.1D, 1E, 1F ).
The early stage, the JNK signaling pathway was still powerfully activated in all brain areas. These findings illustrate that JNK activation persists until 23 weeks of age at an advanced stage of the AS pathology. We measured JNK activation in the post-synaptic elements, in Ube3a m−/p+ hippocampus compared to wt mice. The P-JNK/JNK ratio was significantly higher in Ube3a m−/p+ (50%, p<0.0001, Fig. 2A -B) than wt mice. We also measured the p-PSD95/PSD95 ratio ( Fig. 2A-B) , using a p-PSD95 antibody that recognizes the specific JNK phosphorylation site. The ratio was significantly higher in Ube3a m−/p+ (27%) than wt mice (p<0.01, Fig.2A-B ).
In addition, to analyze the molecular organization of Ube3a m−/p+ post-synaptic elements better, we quantified other PSD markers: Shank3, a scaffold protein strongly implicated in autism, Drebrin, a marker of mature spines and AMPA and NMDA receptors. Shank3 and GLUR2 levels were significantly higher in Ube3a m−/p+ (55% and 53%; p<0.01, p<0.05, Fig. 2A-B ), while Drebrin was 23% lower than in wt mice (p<0.05, Fig. 2A-B ). NR2A, NR2B and GLUR1 levels showed no significantly change in Ube3a m−/p+ ( Fig. 2A-B ). These results indicate abnormal protein expression and/or organization of the PSD region in Ube3a m−/p+ mice.
We analyzed JNK activation at the post-synaptic elements in the cortex as well. The p-JNK/JNK ratio was significantly higher (45%) in Ube3a m−/p+ than wt mice (p<0,0001, Fig. S1A ), indicating JNK activation in the post-synaptic protein-enriched fraction. The p-PSD95/PSD95 ratio was significantly higher in Ube3a m−/p+ (28%) than wt mice (p<0.0001, Fig. S1A ). In Ube3a m−/p+ the Shank3 level was 51% higher and Drebrin 43% lower than in wt mice (p<0.001 and p<0.01, Fig.   S1A ). In addition, N-methyl-D-aspartate receptor 2A NR2A (45%) and AMPA receptor subunits GLUR1 (30%) were significantly lower in Ube3a m−/p+ than in wt mice (p<0.05, p<0.05, Fig. S1A ), while NR2B and GLUR2 levels showed no change ( Fig. S1A ).
Finally, we also examined JNK activation in the post-synaptic elements in the cerebellum, in Ube3a m−/p+ TIF fraction showed significant biomarker changes in the 3 different brain areas analyzed. In order to correlate Ube3a m−/p+ synaptic dysfunctions to both cognitive and locomotor defects we examined cognitive impairment with the Novel Object Recognition Test (NORT) and
locomotor defects with the Open Field and Rotarod tests.
In the NORT, Ube3a m−/p+ mice had a significantly lower discrimination index (DI) (96%) than aged-matched wt mice (p<0,05, Fig. 3A ). At 7 weeks of age the Ube3a m−/p+ DI was 0.009422, and the wt DI 0.2712. These data confirm the severe cognitive impairment in Ube3a m−/p+ mice already at 7 weeks of age.
To investigate spontaneous locomotor and exploratory activity in Ube3a m−/p+ we ran the Open Field test on the same animals. Ube3a m−/p+ mice had significantly lower velocity (15%) and shorter distance moved (14%) than aged-matched wt mice (p<0.05, Fig. 3B ). The total number of crossing was significantly lower too (21%) in Ube3a m−/p+ than wt mice (p<0.05, Fig. 3B ). These data confirm locomotor impairments in Ube3a m−/p+ mice.
Exploratory activity was measured as the time spent in the inner zone and the outer zone ( Fig. 3B) :
Ube3a m−/p+ mice spent more time (9%, p<0.01) in the outer zone of the arena but the time spent in the inner zone was no significantly different from aged-matched wt mice. In addition, Ube3a m−/p+ mice also had an increased hypermobility state (95%, p<0.01, Fig. 3B ) compared to age-matched wt mice. To summarize, Ube3a m−/p+ mice showed a mild exploratory impairment at 7 weeks compared to wt mice but had a severe hypermobility symptom.
The Ube3a m−/p+ locomotor impairment was then characterized in the Rotarod test. Ube3a m−/p+ had a shorter (17%) latency to fall on the accelerated rod than to aged-matched wt mice, with significantly reduced locomotor ability at 7 weeks of age (p<0.05, Fig. 3C ).
These results suggest that Ube3a m−/p+ mice at 7 weeks of age present an important cognitive impairment while the locomotor defects seem milder than in aged-matched wt mice.
J o u r n a l P r e -p r o o f
Journal Pre-proof We characterized the synaptic dysfunction of Ube3a m−/p+ mice at 23 weeks of age. Here we presented only the hippocampal results because the data concerning other areas are in line with hippocampal findings (in supplementary Figs. S2A-B) . The post-synaptic protein-enriched fraction still presented JNK activation, and in fact the p-JNK/JNK ratio was 49% higher in Ube3a m−/p+ than wt (p<0.0001, Fig. 2C-D) . The p-PSD95/PSD95 ratio (22%), Shank3 (47%), NR2A (55%), NR2B
(25%) and GLUR2 (56%) levels were significantly higher in Ube3a m−/p+ than wt mice (p<0.01, p<0.001, p<0.001, p<0.01, p<0.0001, Fig.2C-D) while Drebrin (45%) and GLUR1 (47%) levels were lower than in wt mice (p<0.0001, Fig.2C-D) .
Ube3a m−/p+ mice present behavioral impairments at 23 weeks of age
Cognitive and locomotor defects in Ube3a m−/p+ mice were examined at 23 weeks of age. In the NORT, Ube3a m−/p+ mice had a significantly lower DI than aged-matched wt mice (p<0.001, Fig.   3D ). Wt mice had a DI of 0.272, and Ube3a m−/p+ DI had -0.1352 while at 7 weeks it was 0.009422.
These data indicate that Ube3a m−/p+ cognitive impairments get worse with the progression of the AS pathology.
The Open Field test was run at 23 weeks to assess the spontaneous locomotor and exploratory activity in Ube3a m−/p+ and wt mice. Surprisingly, Ube3a m−/p+ mice did not significantly differ in velocity and distance moved from aged-matched wt mice (Fig. 3E) , indicating no genotypic differences. However, at 23 weeks the total number of crossings was significantly smaller (30%) in Ube3a m−/p+ (p<0.05, Fig. 3E ).
As regards exploratory activity, the time spent by Ube3a m−/p+ mice in the inner zone did not significantly differ from the time spent by aged-matched wt mice (Fig. 3E ), while the time spent in the outer zone was higher (p<0.05, Fig. 3E ).
Finally, Ube3a m−/p+ mice still presented an increased hypermobility (78%, p<0.05, Fig. 3E) compared to age-matched wt mice. The Ube3a m−/p+ mice locomotor impairment at 23 weeks was not significantly different from wt mice, although there were fewer crossings and the evident hypermobility symptoms persisted at this stage of the AS pathology of mice. (Borsello et al., 2003) . In addition, to assess the compensatory effect we also calculated the p-ERK/ERK ratio, as previously observed.
D-JNKI1 powerfully prevented JNK and c-Jun phosphorylation in the hippocampus (44%, p<0.0001; 51%, p<0.01, Fig. 4A ), cortex (55%, p<0.0001; 30%, p<0.001% Fig. S3A ), and cerebellum (26%, p<0.001; 40%, p<0.0001 Fig. S4A ) in the treated compared to untreated Ube3a m−/p+ mice, but had no significant effect in wt mice.
As expected, ERK phosphorylation increased of 79% in the hippocampus (p<0.001, Fig. 4A ), 71%
in the cortex (p<0.001, Fig. S3A ), and 72% in the cerebellum (p<0.0001, Fig. S4A) (Fig. S3B) ; Shank3 was lower as well (70%, p<0.0001, Fig. S3B ), while Drebrin did not significantly change. D-JNKI1 restored NMDA and AMPA receptor levels. NR2A decreased 64% (p<0.0001, Fig. S3B ), NR2B 49% (p<0.01, Fig.   S3B ), GLUR1 39% (p<0.01, Fig. S3B ) and GLUR2 61% (p<0.0001, Fig. S3B ) in treated compared to untreated Ube3a m−/p+ mice. D-JNKI1 normalized the biochemical marker levels of Ube3a m−/p+ treated mice and had no significant effect in wt mice.
Finally, D-JNKI1 at 23 week normalized biochemical marker levels in the cerebellum of Ube3a m−/p+ mice. In the cerebellum, like in the others brain regions, D-JNKI1 reduced the p-JNK/JNK (38%) and p-PSD95/PSD95 (54%) ratios in the post-synaptic protein-enriched fraction compared to untreated Ube3a m−/p+ mice (p<0.001, p<0.0001, Fig. S4B ). Shank3 and Drebrin levels were both regularized, while the treatment raised the NMDA (70%, p<0,05 for NR2B, not significant for NR2A, Fig. S4B ) and AMPA receptor levels (GLUR1 62%, GLUR2 38%, p<0.0001, p<0.01 Fig. S4B ) compared to untreated mice. No significant effects were seen on treated wt mice ( Fig. S4B) .
These data indicate that the D-JNKI1 normalizes biochemical post-synaptic protein-enriched fraction alterations in vivo in the three brain areas studied.
J o u r n a l P r e -p r o o f 
D-JNKI1 rescues cognitive impairments but not locomotor defects
To evaluate the potential neuroprotective effect of D-JNKI1 on cognitive impairment we investigated untreated and treated Ube3a m−/p+ and wt mice in the NORT during chronic treatment at the indicated times (from 7 to 23 weeks). The Ube3a m−/p+ DI was always lower than aged-matched wt mice, and the genotypic difference increased with the severity of the AS-pathology as expected (159% p<0.0001, Fig. 5A1-A2) . At 23 week the Ube3a m−/p+ had a significantly lower DI than agedmatched wt mice. D-JNKI1 had no effect in wt in fact the two curves (continue and dotted) overlap ( Fig. 5A4 ). However, with the chronic D-JNKI1 treatment we found a significant difference between treated Ube3a m−/p+ and untreated mice; their performances were significantly better (144%) at 23 weeks of age, reaching an average DI of 0.31 compared to untreated Ube3a m−/p+ (average DI of -0.1352, Fig. 5A3 ). D-JNKI1 rescued the cognitive impairment in Ube3a m−/p+ mice. D-JNKI1's effect on the locomotor defect was investigated in the Rotarod test because, at 23 weeks, the genotypic differences between Ube3a m−/p+ and wt mice were not significantly different in the Open Field test (see Fig. 3E ) while in the Rotarod the differences remained significant. In the four groups previously described (untreated and treated wt and Ube3a m−/p+ mice) from 7 to 23 weeks of age, there was an overall genotypic difference between wt and Ube3a m−/p+ mice (p <0.0001, Fig.   5B1-B2) . At the last time point, Ube3a m−/p+ mice spent 13% less time on the rotating bar than wt mice Fig. 5B2 ). We found no significant effect in treated Ube3a m−/p+ and untreated Ube3a m−/p+ (Fig.   5B3 ). D-JNKI1 had no effect in treated vs untreated wt mice (continue vs dotted lines) ( Fig. 5B4 ).
In conclusion chronic D-JNKI1 treatment had no positive effect on locomotor impairments. J o u r n a l P r e -p r o o f
Discussion
The Ube3a maternal deficient mouse model recapitulates different pathological symptoms associated with AS syndrome including impaired hippocampal long-term potentiation and reduced dendritic spine density, together with cognitive and motor deficits and inducible seizures (Dindot et al., 2008; Jiang et al., 1998; Sato and Stryker, 2010; Weeber et al., 2003; Yashiro et al., 2009) .
Although mutations in the UBE3A gene result in AS pathology, little is known yet about the role of UBE3A in the nervous system and/or how UBE3A mutation/loss induces neuronal degeneration, with consequent cognitive and locomotor impairments. The cellular mechanisms of the downstream effects of UBE3A loss in neurons are still lack, thus there are still no effective treatments.
This study sheds new light on the neuronal alterations caused by UBE3A mutation/loss of function and provides the first proof of principle of an important downstream JNK role in Ube3a m−/p+ pathology.
We report here that Ube3a m−/p+ mice presented high JNK activation both in the soma and in postsynaptic elements. The JNK pathway is activated in the early stage of AS pathology, at 7 weeks of age (a stage comparable to adolescence), and still persists in adulthood (23 weeks), suggesting an important function of this stress pathway in AS. The high JNK activation in the brain of Ube3a m−/p+ is balanced, as often happens, by a drop in ERK phosphorylation.
We also found that Ube3a m−/p+ mice had changes in the PSD marker levels in the post-synaptic protein-enriched fraction, indicating more immature spines. These generalized alterations of the PSD markers in cortex, cerebellum and hippocampus, caused by the loss of UBE3A, are in line with the reduced dendritic spine density observed in AS patients (Jay et al., 1991) and AS mouse models (Cooper et al., 2003; Dindot et al., 2008; Sato and Stryker, 2010; Wallace et al., 2012; Yashiro et al., 2009 ).
With the PSD marker levels alterations in the post-synaptic element we also found powerful JNK activation, at 7 and at 23 weeks of age, suggesting that JNK pathway is involved in synaptic dysfunction in AS, as reported in other brain disease models (Buccarello et al., 2018; Sclip et al., 2014 Sclip et al., , 2013 Sclip et al., , 2011 In neurodegenerative processes, JNK has a double function: it phosphorylates the transcription factor c-Jun in the nucleus, thus activating the neuronal death program, and phosphorylates PSD95, alterating PSD marker levels (Sclip et al., 2013 as well as the morphological structure of the postsynaptic element (Sclip et al., 2014) .
Ube3a m−/p+ mice had higher levels of p-c-Jun in the brain than wt mice, indicating the activation of neuronal death pathway. These mice also showed synaptic dysfunction, as demonstrated by changes in the PSD biomarkers of the post-synaptic protein-enriched fraction, together with JNK activation, confirmed by the specific increase of the p-PSD95/PSD95 ratio in the post-synaptic elements. This is the first neurodegenerative event that can progress in neuronal death.
This is the first indication that, in the brain, the loss of E3 ubiquitin ligase UBE3A activates the JNK stress signaling pathway. However, to determine the importance of JNK's role in this AS model, we applied a chronic, specific inhibition of JNK in Ube3a m−/p+ mice to see whether JNK inhibition blocked AS pathology and could offer a new pharmacological opportunity against AS.
D-JNKI1 treatment in Ube3a m−/p+ mice, starting at 7 weeks of age and ending at 23 weeks of age, inhibited c-Jun phosphorylation in Ube3a m−/p+ in all the brain areas studied in vivo. Furthermore, by inhibiting JNK signaling, the p-ERK/ERK ratio increased up to wt level, as expected. It is well known that c-Jun is the elective target of JNK and, importantly, it is phosphorylated in response to many different stress stimuli. c-Jun is involved in multiple cellular processes like gene expression, apoptosis, metabolism and other critical physiological responses (Kuan et al., 1999; Yang et al., 1997) .
Notably, JNK inhibition (D-JNKI1) powerfully inhibits the phosphorylation of c-Jun in the nuclei of cortical, hippocampal and cerebellar neurons, preventing their neurodegenerative pathway. In addition, the treatment also normalized the previously observed biochemical alterations in the postsynaptic protein-enriched fraction, and the p-JNK/JNK and p-PSD95/PSD95 ratios were reduced in all the brain areas.
The neuroprotection on the post-synaptic elements is paired by the NORT results: D-JNKI1 rescued Ube3a m−/p+ cognitive impairments to the control level. Both the biochemical and functional findings strengthen the neuroprotection obtained with D-JNKI1, giving hope for a possible clinical application. Last but not least, D-JNKI1 treatment in wt mice did not show any significant adverse J o u r n a l P r e -p r o o f effects. The treatment also powerfully inhibits the c-jun phosphorylation in the cortex, hippocampus and cerebellum, preventing the neurodegenerative-stress pathway.
This is the first proof of concept that in the brain the E3 ubiquitin ligase UBE3A loss induces the downstream activation of the JNK stress signaling pathway. This link between UBE3A and JNK may be indirect, but is pivotal in the AS. In fact, the specific inhibition of JNK prevents c-Jun phosphorylation, rescues the spine alterations and the cognitive impairments in Ube3a m−/p+ mice, tackles the pathology.
In our opinion these data provide evidences of the therapeutical utility of D-JNKI1 treatment against AS.
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